Faisal Mehmud
About Faisal Mehmud
Dr. Faisal Mehmud is Chief Medical Officer (CMO) of Medicus Pharma Ltd. (Nasdaq: MDCX) since November 2024; he is 50 years old and operates across London, Paris, and Philadelphia, with 20+ years in clinical development, medical affairs, and drug safety spanning oncology, hematology, rare diseases, and primary care . He holds a medical degree from the University of Cambridge, diplomas in internal and pharmaceutical medicine from the Royal College of Physicians, and a UK General Medical Council license . Company filings do not disclose TSR, revenue growth, or EBITDA growth metrics tied to Mehmud’s compensation; the executive compensation program generally emphasizes base salary and equity incentives without formal performance goals or weights .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| GlaxoSmithKline (GSK) | Senior Vice President, Data Generation & Scientific Communications, Worldwide Global Medical Affairs | Not disclosed | Led interventional/non‑interventional clinical trials; advanced medical lifecycle strategies across small molecules, antibodies, cell therapies, and cytotoxic chemotherapies . |
| Pfizer | Vice President; Worldwide Medical Franchise Head, Precision Medicine & Early Oncology Development | Not disclosed | Advanced precision oncology portfolio from early development to market readiness; bridged scientific innovation with commercial strategy . |
| Bristol Myers Squibb (BMS) | Vice President, Global Drug Safety | Not disclosed | Oversaw safety risk management for complex antibody-based and cellular therapies . |
| Sanofi; Novartis | Senior roles (details not specified) | Not disclosed | Senior medical leadership roles across therapeutic areas (specific responsibilities not detailed) . |
External Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Antev Limited (Medicus subsidiary) | Co‑Chairman, Board of Directors | Appointed September 2, 2025 | Strengthens governance and development of Teverelix (GnRH antagonist) targeting AUR relapse and high CV‑risk prostate cancer; supports ~$6B market opportunity thesis . |
Fixed Compensation
- Employment agreement: Medicus entered into an employment agreement with Dr. Mehmud dated November 14, 2024 (filed as Exhibit 10.7), providing for base salary and an annual discretionary bonus; agreements include notice and payments for termination without cause or change of control, and one‑year non‑compete/non‑solicit post‑termination .
- Specific base salary, target bonus %, and actual bonus paid for Dr. Mehmud are not disclosed in the DEF 14A or S‑1 summaries; NEO compensation tables for 2024 list CEO, CFO, and CSO only .
Performance Compensation
| Metric/Instrument | Weighting | Target | Actual/Payout | Vesting |
|---|---|---|---|---|
| Annual discretionary bonus | Not specified | Prescribed milestones at CEO’s discretion; subject to company performance, financial stability, and cash availability (structure disclosed for other exec agreements and described generally) | Not disclosed | N/A . |
| Equity incentives (Options/RSUs) | Not specified | Committee‑determined; RSUs cannot vest before 1 year; options per plan/agreements | Not disclosed | RSUs: ≥1‑year minimum; options per award terms/time‑based vesting used for retention . |
The Compensation Committee has not established formal criteria or goals tied to total compensation; equity incentives utilize time vesting for retention .
Equity Ownership & Alignment
| Item | As disclosed | Notes |
|---|---|---|
| Beneficial ownership (Common Shares) | Not presented (dash) in beneficial ownership table as of June 2, 2025 | Dr. Mehmud’s line shows “–”, indicating no share count disclosed in the table at that date . |
| Options/RSUs outstanding | Not detailed for Mehmud in NEO “Outstanding Equity Awards” tables | 2024 NEO tables cover CEO, CFO, CSO; Form 3 for Mehmud amended to correct his options vesting schedule (existence of options inferred) . |
| Hedging policy | Hedging transactions prohibited for executives and directors | Prohibits prepaid variable forwards, equity swaps, collars, exchange funds; insider trading/blackout policies in place . |
| Clawback policy | Adopted; applies to erroneously awarded incentive pay over past three completed fiscal years upon restatement | Filed as exhibit to Form 10‑K; SEC/Nasdaq compliant . |
| Pension/SERP | No pension plan | No pension benefits awarded in 2024 . |
Employment Terms
| Term | Disclosure for Dr. Mehmud |
|---|---|
| Start date; role | CMO since November 2024 . |
| Agreement date; type | Employment Agreement dated November 14, 2024 (Exhibit 10.7) . |
| Cash comp | Base salary + annual discretionary bonus (specific amounts not disclosed in summaries) . |
| Termination | Notice and payment requirements upon termination without cause; payments upon change‑of‑control (specific amounts/structure for Mehmud not detailed in summaries) . |
| Non‑compete / Non‑solicit | 1‑year non‑compete and non‑solicit post‑termination . |
| Equity treatment | Equity awards governed by Equity Incentive Plan; RSUs ≥1‑year minimum vest; option terms per award; committee discretion . |
| Clawback / Hedging | Clawback policy adopted; hedging prohibited . |
| Insider filings | Company noted Form 3 amendment for Mehmud to correct options vesting schedule; otherwise 2024 filings deemed timely except listed corrections . |
Compensation Committee Analysis
- Structure: Compensation comprises base salary and equity participation under the Equity Incentive Plan; committee emphasizes competitive pay to attract/retain, and time‑vested equity for retention .
- Process and risk: No formal quantitative goals; committee/broad discretion considers company performance, individual KPIs, and peer benchmarking; the Board/committee monitor compensation risks and prohibit hedging to align executives with shareholders .
- Charter responsibilities include CEO/senior executive goals, succession planning, use of independent compensation consultants, and long‑term incentive plan administration .
Say‑on‑Pay & Shareholder Feedback
- As an Emerging Growth Company, Medicus is not required to conduct advisory votes on NEO compensation or its frequency; reduced compensation disclosure requirements apply .
Performance & Track Record (Executive)
- Executive achievements: Led global data generation and clinical trials (GSK); advanced precision oncology programs to market readiness (Pfizer); directed global drug safety for complex therapies (BMS) .
- Education/credentials: MD (University of Cambridge); diplomas in internal and pharmaceutical medicine; UK GMC medical license .
Risk Indicators & Red Flags (specific to Mehmud)
- Section 16 filings: Company disclosed an amendment to Mehmud’s Form 3 to correct the options vesting schedule—an administrative correction; no legal proceedings disclosures for him in the period covered .
- Hedging/pledging: Hedging prohibited; no pledging disclosures specifically identified for Mehmud .
- Pension/tax: No pension plan; no tax gross‑ups disclosed in the sections reviewed .
Investment Implications
- Alignment: Time‑vested equity and hedging prohibition support alignment; however, lack of disclosed personal share ownership as of June 2, 2025 and absence of performance‑based metrics/weights may temper pay‑for‑performance confidence for this role .
- Retention: One‑year non‑compete/non‑solicit and formal employment agreement enhance retention/transition protections; equity plan’s ≥1‑year RSU minimum and committee discretion can be used to reinforce retention .
- Execution leverage: External board leadership at Antev ties Mehmud to Medicus’s pipeline expansion (Teverelix), potentially increasing strategic impact; monitoring future equity grants, vesting schedules, and any Form 4 activity will be key to assessing selling pressure .
- Governance: EGC status limits say‑on‑pay; the adopted clawback and insider trading controls mitigate governance risk, but investors should watch for future disclosure of CMO‑specific salary/bonus/award terms and any change‑of‑control economics in the filed employment agreement exhibits .